Prime Medicine (PRME) Current Assets (2021 - 2026)

Prime Medicine (PRME) has 6 years of Current Assets data on file, last reported at $137.9 million in Q1 2026.

• Quarterly Current Assets fell 15.8% year-over-year to $137.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $137.9 million (down 15.8% YoY) and the FY2025 annual result came in at $181.3 million, down 14.44% from the prior year.
• Current Assets eased to $137.9 million in Q1 2026, from $181.3 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $296.6 million in Q4 2022 to a low of $121.3 million in Q2 2025.
• A 5-year average of $195.1 million and a median of $184.5 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets slumped 51.8% — and 2024, when it soared 48.2%.
• Tracing PRME's Current Assets over 5 years: stood at $296.6 million in 2022, then tumbled by 51.8% to $143.0 million in 2023, then soared by 48.2% to $211.9 million in 2024, then retreated by 14.44% to $181.3 million in 2025, then retreated by 23.94% to $137.9 million in 2026.
• The last three Current Assets figures came in at $137.9 million (Q1 2026), $181.3 million (Q4 2025), and $231.4 million (Q3 2025), per Business Quant data.